Evidence map›Paper›PMID 33021790›Full record

ArticleJournal of natural products2020

CRISPR-Cas9 Genome-Wide Knockout Screen Identifies Mechanism of Selective Activity of Dehydrofalcarinol in Mesenchymal Stem-like Triple-Negative Breast Cancer Cells.

Corena V Grant, Shengxin Cai, April L Risinger, Huiyun Liang, Barry R O'Keefe, John G Doench, Robert H Cichewicz, Susan L Mooberry

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of natural products, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Corena V Grant
Shengxin CaiNatural Products Discovery Group, Institute for Natural Products Applications and Research Technologies, Department of Chemistry & Biochemistry, Stephenson Life Science Research Center, University of Oklahoma, Norman, Oklahoma 73019, United States.
April L RisingerORCID 0000-0002-4363-3268
Huiyun Liang
Barry R O'KeefeNatural Products Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, and Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702, United States.ORCID 0000-0003-0772-4856
John G DoenchBroad Institute of Harvard and MIT, Cambridge, Massachusetts 02142, United States.
Robert H CichewiczNatural Products Discovery Group, Institute for Natural Products Applications and Research Technologies, Department of Chemistry & Biochemistry, Stephenson Life Science Research Center, University of Oklahoma, Norman, Oklahoma 73019, United States.ORCID 0000-0003-0744-4117
Susan L MooberryORCID 0000-0001-8575-2516

Funding

New Leads for Triple Negative Breast Cancer from Diverse Natural SourcesU01CA182740 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI CICHEWICZ, ROBERT HENRY, MOOBERRY, SUSAN L · 2014 to 2018
$2.3M
NCI NIH HHS U01 CA182740
6 · The paper itself

Abstract

There are no targeted therapies available for triple-negative breast cancers (TNBCs) in part because they represent a heterogeneous group of tumors with diverse oncogenic drivers. Our goal is to identify targeted therapies for subtypes of these cancers using a mechanism-blind screen of natural product extract libraries. An extract from

Indexed as

CRISPR-Cas Systems17-Hydroxysteroid DehydrogenasesAldehyde OxidoreductasesAntineoplastic Agents, PhytogenicBreast NeoplasmsCell Line, TumorFemaleGene Knockout TechniquesHumansMolecular StructureNeoplastic Stem CellsPPAR gammaRNA, Small InterferingTriple Negative Breast Neoplasms17-Hydroxysteroid DehydrogenasesAldehyde OxidoreductasesAntineoplastic Agents, PhytogenicHSD17B11 protein, humanPPAR gammaRNA, Small Interfering

Identifiers

PMID33021790
PMCPMC7722265

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.